17 Oct Tabla comparativa entre AINEs

Publicado en 18:20h en Dolor por
2 Likes
Tiempo de lectura: 5 minutos
Referencias:
  1. FT del producto Xumer
  2. FT del producto Flodin
  3. FT del producto Motrin
  4. FT del producto Advil
  5. FT del producto Voltaren
  6. FT del producto Apronax
  7. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004 May;18(7):790-804. doi: 10.1096/fj.03-0645rev.
  8. Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;2015(9):CD008659. Published 2015 Sep 28. doi:10.1002/14651858.CD008659.pub3
  9. Nekoofar MH, Sadeghipanah M, Dehpour AR. Evaluation of meloxicam (A cox-2 inhibitor) for management of postoperative endodontic pain: a double-blind placebo-controlled study. J Endod. 2003 Oct;29(10):634-7. doi: 10.1097/00004770-200310000-00005.
  10. Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014 May 8;2014(5):CD004309. doi: 10.1002/14651858.CD004309.pub4.
  11. Calvo AM, Sakai VT, Giglio FP, Modena KC, Colombini BL, Benetello V, Sakamoto FC, Freire TM, Dionísio TJ, Lauris JR, Trindade AS Jr, Faria FA, Santos CF. Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study. Int J Oral Maxillofac Surg. 2007 Jan;36(1):26-31. doi: 10.1016/j.ijom.2006.09.006.
  12. Malmstrom K, Sapre A, Couglin H, Agrawal NG, Mazenko RS, Fricke JR Jr. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther. 2004 May;26(5):667-79. doi: 10.1016/s0149-2918(04)90067-7.
  13. Auvinet B, Ziller R, Appelboom T, Velicitat P. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin Ther. 1995 Nov-Dec;17(6):1078-98. doi: 10.1016/0149-2918(95)80086-7.
  14. Li H, Mandema J, Wada R, Jayawardena S, Desjardins P, Doyle G, Kellstein D. Modeling the onset and offset of dental pain relief by ibuprofen. J Clin Pharmacol. 2012 Jan;52(1):89-101. doi: 10.1177/0091270010389470.
  15. Scholer DW, Ku EC, Boettcher I, Schweizer A. Pharmacology of diclofenac sodium. Am J Med. 1986 Apr 28;80(4B):34-8. doi: 10.1016/0002-9343(86)90077-x.
  16. Chang DJ, Desjardins PJ, Chen E, Polis AB, McAvoy M, Mockoviak SH, Geba GP. Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial. Clin Ther. 2002 Apr;24(4):490-503. doi: 10.1016/s0149-2918(02)85126-8.
  17. Colberg K, Hettich M, Sigmund R, Degner FL. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Curr Med Res Opin. 1996;13(7):363-77. doi: 10.1185/03007999609111556.
  18. Gaston G. A double-blind, randomized, parallel-group study of the pharmacokinetics and onset of action of Naprelan in patients following oral surgery. Am J Orthop (Belle Mead NJ). 1996 Sep;25(9 Suppl):37-41.
  19. Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6):1152-60. doi: 10.1136/annrheumdis-2015-207677.
  20. Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012;6:6-20. doi:10.2174/1874312901206010006
  21. Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi: 10.1371/journal.pone.0190798.
  22. Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A. Cyclooxygenase-2 selective non-steroidal anti-inflammatory (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis or rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12(11)
  23. Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007 Dec;15(12):1348-56. doi: 10.1016/j.joca.2007.05.022.
  24. Curtis SP, Bockow B, Fisher C, Olaleye J, Compton A, Ko AT, Reicin AS. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord. 2005 Dec 1;6:58. doi: 10.1186/1471-2474-6-58.
  25. Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. doi: 10.1136/ard.2006.059162.
  26. Morales DR, Lipworth BJ, Guthrie B, Jackson C, Donnan PT, Santiago VH. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. J Allergy Clin Immunol. 2014 Jul;134(1):40-5. doi: 10.1016/j.jaci.2013.10.057.
  27. Llanora GV, Loo EX, Gerez IF, Cheng YK, Shek LP. Etoricoxib: a safe alternative for NSAID intolerance in Asian patients. Asian Pac J Allergy Immunol. 2013 Dec;31(4):330-3. doi: 10.12932/AP0290.31.4.2013.
  28. Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Int Arch Allergy Immunol. 2007;142(1):64-9. doi: 10.1159/000096000
  29. van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015;17(1):66. Published 2015 Mar 19. doi:10.1186/s13075-015-0554-0
  30. Martín Arias LH, Martín González A, Sanz Fadrique R, Vazquez ES. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies. J Clin Pharmacol. 2019 Jan;59(1):55-73. doi: 10.1002/jcph.1302.
  31. Kristensen LE, Jakobsen AK, Askling J, Nilsson F, Jacobsson LT. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2015 Aug;67(8):1137-49. doi: 10.1002/acr.22555.
  32. Bessone F, Hernandez N, Roma MG, Ridruejo E, Mendizabal M, Medina-Cáliz I, Robles-Díaz M, Lucena MI, Andrade RJ. Hepatotoxicity induced by coxibs: how concerned should we be? Expert Opin Drug Saf. 2016 Nov;15(11):1463-1475. doi: 10.1080/14740338.2016.1225719.
Referencias:
  1. 1. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004 May;18(7):790-804. doi: 10.1096/fj.03-0645rev
  2. Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;2015(9):CD008659. Published 2015 Sep 28. doi:10.1002/14651858.CD008659.pub3
  3. Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014 May 8;2014(5):CD004309. doi: 10.1002/14651858.CD004309.pub4.
  4. Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007 Dec;15(12):1348-56. doi: 10.1016/j.joca.2007.05.022.
  5. Curtis, S.P., Bockow, B., Fisher, C. et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord 6, 58 (2005). http://doi.org/10.1186/1471-2474-6-58
  6. Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. doi: 10.1136/ard.2006.059162.
  7. Martín Arias LH, Martín González A, Sanz Fadrique R, Vazquez ES. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies. J Clin Pharmacol. 2019 Jan;59(1):55-73. doi: 10.1002/jcph.1302.

Este material ha sido revisado por el Departamento Médico de Tecnofarma Perú. Material de uso exclusivo para profesionales de la salud.
Código material: 0723_PARACETAMOLAINESDIG_DOL

¡Haz clic para calificar esta publicación!
No Comments

Lo sentimos, el formulario de comentarios está cerrado en este momento.

Share